Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04876391 · ClinicalTrials.gov registry record · Phase 2
A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04876391 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 45 participants.
The verdict
NCT04876391, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with hidradenitis suppurativa in the long-term. Participants are in this study for about 2 years and 4 months. For 2 years, participants visit the study site every 2 weeks to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' hidradenitis suppurativa and collect information on any health problems of the participants.
Interventions
- DRUG Spesolimab 1200 mg
- DRUG Spesolimab 600 mg
- DRUG Placebo matching 600 mg Spesolimab
- DRUG Placebo matching 1200 mg Spesolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04876391
The ClinicalTrials.gov registry entry for NCT04876391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Spesolimab 1200 mg is the first listed.
NCT04876391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04876391 about?
NCT04876391 is a clinical study titled "A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial". This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with hidradeni...
What is the current status of trial NCT04876391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2021-08-24. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT04876391?
The interventions under investigation include: Spesolimab 1200 mg (DRUG), Spesolimab 600 mg (DRUG), Placebo matching 600 mg Spesolimab (DRUG), Placebo matching 1200 mg Spesolimab (DRUG).
Who is sponsoring clinical trial NCT04876391?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.